Answers are grounded in this paper and cite their sources.
Alzheimer’s disease (AD) is a complex neurodegenerative disorder characterized by amyloid-β accumulation, tau pathology, neuroinflammation, synaptic dysfunction, and progressive cognitive decline. Despite advances in experimental modeling and biomarker development, no single model or assay captures the biological complexity, age-related features, systemic influences, and clinical heterogeneity of human AD. This review critically evaluates multimodal assay platforms for investigating AD pathogenesis and therapeutic responses across experimental and translational scales. We define multimodal assay platforms as coordinated designs integrating three functionally linked components: (i) disease models in which defined biological processes can be observed or perturbed; (ii) experimental and clinical assays that generate complementary molecular, cellular, functional, imaging, and biofluid readouts; and (iii) human-reference datasets, biomarker-classification frameworks, and computational approaches that benchmark and interpret these readouts in relation to human AD. Multimodality therefore assigns each component a distinct inferential role-mechanistic discovery, causal interrogation, orthogonal validation, or translational anchoring, rather than simply accumulating techniques. We provide a question-driven roadmap linking biological questions to complementary model combinations and readouts while benchmarking their translational relevance against human-reference data. We discuss conventional in vitro models, emerging three-dimensional platforms, and genetic, induced, and humanized chimeric animal models. Finally, we examine how high-throughput screening, biofluid biomarkers, neuroimaging, amyloid/tau/neurodegeneration (AT(N))-based classification, multi-omics, and artificial intelligence (AI)-assisted computational approaches complement experimental platforms. Collectively, these platforms provide a tiered translational roadmap for model selection, mechanistic interpretation, and biomarker-informed therapeutic development.
No takes yet. Share an insight, caveat, or question.
Baek et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: